The Prescription Drug Affordability Board (PDAB) posted the agenda for the next Stakeholder Council meeting on December 16 at 2:00 pm. You must register for the meeting to receive the log-in information. More information about the Stakeholder Council and the PDAB are available through their webpage.

For more information, contact NACDS’ Jill McCormack at 717-592-8977.

The Prescription Drug Affordability Board (PDAB) is soliciting comments informing the development of draft regulations to implement its plan to determine upper payment limits for drugs of concern. The General Assembly’s Legislative Policy Committee approved the plan last week, clearing it to move ahead to the regulatory stage. Comments should be submitted to comments.pdab@maryland.gov by November 8, 2024. 

• Amendments to COMAR 14.01.01.01 (Definitions) 

• New Regulation COMAR 14.01.01.06 (Hearing Procedures) 

• New Chapter – COMAR 14.01.05 (Policy Review, Final Action, Upper Payment Limits)  

• Farxiga, Jardiance, Ozempic and Trulicity (Clinical input on Upper Payment Limits Plan for each drug)

For more information, contact NACDS’ Jill McCormack at 717-592-8977.

COMAR 10.34.42 Pharmacist Prescribing of a Nicotine Replacement Therapy went into effect on October 14. This service is covered by Medicaid for enrolled pharmacies/pharmacists. These regulations are the result of the enactment of SB 62 of 2023 and payment for pharmacy services (Medicaid and commercial plans) as required by HB 1151 of 2023.

For more information, contact NACDS’ Jill McCormack at 717-592-8977.

The Prescription Drug Affordability Board (PDAB) and Stakeholder Council (PDASC) announced upcoming meeting schedules:

• The Prescription Drug Affordability Board Stakeholder Council (PDASC) will meet on November 4 at 2:00 pm. The meeting information page includes a link to register for the virtual meeting. They will not meet on October 21 or 28.
• The Prescription Drug Affordability Board (PDAB) will only have one meeting in October; a virtual Ad-Hoc meeting is scheduled to be held on October 28 at 2:00 pm. The meeting information page includes a link to register and additional information.

For more information, contact NACDS’ Jill McCormack at 717-592-8977.

The Prescription Drug Affordability Board (PDAB) has rescheduled its September 23 Board meeting for September 10. Registration is required to participate. The Board welcomes public comment and input on all its work. Additional information about providing public comment can be found on the Board Meetings page of the PDAB’s website.

For more information, contact NACDS’ Jill McCormack at 717-592-8977.

The Prescription Drug Affordability Board (PDAB) invites you to attend the August meeting of its Stakeholder Council at 2:00 pm on August 26 virtually. The agenda and other meeting materials and registration link will be available on the Stakeholder Council page of the PDAB’s website prior to the scheduled meeting. To register for oral public comments and for additional information, please refer to the Stakeholder Council page.

For more information, contact NACDS’ Jill McCormack at 717-592-8977.

The Prescription Drug Affordability Board (PDAB) has selected 6 drugs they propose to subject to a cost review process. If members wish to submit comments on any or all the choices, please send them to comments.pdab@maryland.gov with the subject line: Board Selected Drugs (Drug Name) by July 22. For more information on the PDAB or on the comment process, see the PDAB’s Board Selected Drugs Page.

Also in Maryland, Medicaid Fee-For-Service released Advisory #263 in reference to the Generic vs. Brand Status on Medicaid’s Preferred Drug List (PDL) effective July 1, 2024.

For more information, contact NACDS’ Jill McCormack at 717-592-8977.

The Prescription Drug Affordability Board (PDAB) announced the June virtual meeting of its Stakeholder Council, scheduled for 2:00 pm on June 24. The agenda and other meeting materials will be available on the Stakeholder Council page of the PDAB’s website prior to the scheduled meeting. To register for the June 24 virtual meeting, please click on this link and enter the required information. After registering, you will receive a confirmation email containing details about joining the meeting. Also, to register for oral public comment and for additional information concerning public comments, please refer to the Stakeholder Council page.

Also in Maryland, please visit the Prescription Drug Affordability Board’s, Cost Review Study Process page on the Board’s website to learn more about the comment period for “Board Selected Drugs for Cost Review.” The 60-day comment period will close on July 22, 2024.  

For more information, contact NACDS’ Jill McCormack at 717-592-8977.

At its May 20 meeting, the Prescription Drug Affordability Board selected six prescriptions drugs for cost review studies.

For more information, contact NACDS’ Jill McCormack at 717-592-8977.